Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

NCT03994913 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: CAR-CD19 T Cells

Sponsor

CARsgen Therapeutics Co., Ltd.

Collaborators

[object Object]
[object Object]